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Abstract
The etiology of osteoarthritis is multifactorial, with inflammatory,
metabolic, and mechanical causes. Pain in osteoarthritis is
initiated by mild intra-articular inflammation and degeneration of
articular cartilage and subchondral bone. The principle of
treatment with acetaminophen or non-steroidal anti-
inflammatory drugs is to reduce pain and improve joint function.
Recently, animal models for osteoarthritic pain behavior have
been established. The most frequently used rat model for
analyzing properties of drugs on the pathology of osteoarthritis
is the injection of the metabolic inhibitor monosodium
iodoacetate into the joint, which inhibits the activity of
glyceraldehyde-3-phosphate dehydrogenase in chondrocytes.
Here, we characterize the effect on pain behavior of lacosamide,
a member of a family of functionalized amino acids that are
analogues of endogenous amino acids and D-serine, in the
monosodium iodoacetate rat model for osteoarthritis in
comparison to diclofenac and morphine. Lacosamide (3, 10,
and 30 mg/kg) was able to reduce secondary mechanical
allodynia and hyperalgesia similarly to morphine (3 mg/kg). In
contrast, diclofenac (30 mg/kg) was only effective in reducing
secondary mechanical hyperalgesia. During the first week, pain
is induced mainly by inflammation in the iodoacetate model, but
afterwards inflammation plays only a minor role in pain.
Lacosamide was able to inhibit pain at days 3, 7 and 14 after
induction of arthritis. This shows that lacosamide is able to
reduce pain behavior induced by multiple mechanisms in
animals.
Introduction
Osteoarthritis is the most common form of joint disease and a
leading cause of chronic pain and disability [1]. Its prevalence
after age 65 is about 60% in men and 70% in women [2].
Osteoarthritis is primarily noted in hands, knees, hips, and
spine and involves degeneration of articular cartilage as well
as changes to the subchondral bone, variable degrees of mild
synovitis and thickening of the joint capsule. Characteristic
osteoarthritis features are seen in X-ray examination of joints.
However, the pathophysiology behind the structural changes
associated with this disease is complex and the link to pain is
poorly understood [3].
Pain is the predominant clinical feature, yet therapy is ineffec-
tive for many patients. Drugs that modify disease progression
represent the ultimate goal of treatment but are not clinically
available. Treatment is currently based on symptomatic relief
of pain and inflammation associated with osteoarthritis to
increase joint function. Non-steroidal anti-inflammatory drugs
(NSAIDs) and acetaminophen are the most widely used drugs
but cyclooxygenase 2 inhibitors, steroids, and opiates are pre-
scribed as well [4].
Several arthritis animal models have been established [5]. One
of the best characterized rat models for analyzing properties of
drugs on the pathology of osteoarthritis is the injection of the
metabolic inhibitor monosodium iodoacetate (MIA) into the
joint, which inhibits the activity of glyceraldehyde-3-phosphate
dehydrogenase in chondrocytes, resulting in disruption of gly-
colysis and eventually in cell death [6,7]. The progressive loss
of chondrocytes results in histological and morphological
changes of the articular cartilage, closely resembling those
seen in osteoarthritis patients. However, analysis of pain
behavior has only recently been established in the iodoacetate
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model [8-11]. In a previous study the anticonvulsant gabapen-
tin was able to reduce secondary mechanical allodynia but not
hyperalgesia in the iodoacetate rat model [12]. Thus, in order
to improve the knowledge on basic pathophysiological mech-
anisms of osteoarthritis pain, the characterization of animal
osteoarthritis pain models and treatment regimens need to be
improved.
This study aimed to identify the antinociceptive effect of
lacosamide (SPM 927, previously referred to as harkoseride
(R)-2-acetamido-N-benzyl-3-methoxypropionamide, ADD
234037), a member of a series of functionalized amino acids
that were specifically synthesized as anticonvulsive drug can-
didates, in the iodoacetate rat model in comparison to mor-
phine (μ-opioid receptor agonist) and diclofenac (NSAID).
Lacosamide has been shown to be active in animal models for
inflammatory pain [13], for diabetic neuropathic pain [14], and
in a small-scale controlled trial of lacosamide in patients with
neuropathic pain [15]. Currently, lacosamide is in phase 3 clin-
ical development for neuropathic pain and epilepsy.
Materials and methods
Animals
All experiments were carried out in accordance with the guide-
lines of the committee for Research and Ethical Issues of The
International Association for the Study of Pain® (IASP) and in
accordance with the institutional guidelines.
Male Wistar rats (Janvier, Le Genest Saint Isle, France) weigh-
ing 170 to 200 g at the start of the experiments were used.
The animals were group-housed (3 animals per cage) in a
room with controlled temperature (21 to 22°C), and a reversed
light-dark cycle (12 h/12 h), and they had access to food and
water ad libitum.
Development of osteoarthritis in the rat
Osteoarthritis was induced by intra-articular injection of 50 μl
of 3 mg MIA (Sigma, Lyon, France) through the patellar liga-
ment of the right knee. Control rats were injected with an
equivalent volume of saline. Up to five days after the MIA injec-
tion a substantial inflammation of synovial joints was observed
in this model. The general health of the animals was monitored.
No signs of distress were seen.
Histology
In a satellite group, histological changes were assessed to
confirm the success of the induction of the arthritis of the rat
knee joints before and on days 3 and 14 after MIA injection.
Knee joints were removed and fixed overnight in 10% formalin
and subsequently decalcified by 10% formic acid for 72 h
before being embedded in paraffin. Frontal sections (10 μm
thick) of the medial aspect of the rat knee joints were prepared
every 250 μm. Hematoxylin and eosin staining was carried out
to assess the extent of inflammatory infiltrates in the joints and
surrounding tissues and safranin-O fast green staining was
done to measure the degeneration of cartilage.
Evaluation of the effect of lacosamide on nociception in 
vehicle treated animals
Before testing the effect of lacosamide on MIA-injected ani-
mals, lacosamide was tested in a control experiment for its
possible autonomic influence on pain behavior. Rats were
tested in the von Frey test in comparison to vehicle rats 30
minutes post-intraperitoneal treatment with 8, 16, and 32 mg/
kg lacosamide.
Evaluation of the effect of compounds on nociception
In the first round of experiments, the MIA-treated rats were ran-
domized to 6 experimental groups (12 animals per group),
which received the following treatments on the days of pain
assessment (days 3, 7 and 14 post-MIA treatment): oral gav-
age of saline (vehicle); oral gavage of 3, 10 or 30 mg/kg
lacosamide; subcutaneous injection of 3 mg/kg morphine.
Diclofenac (30 mg/kg, subcutaneous) was tested in a sepa-
rate experiment but by the same scientists under the same
conditions at about the same time. The non-MIA-treated con-
trol group (control) received oral gavage of saline 45 minutes
prior to the pain assessment. Lacosamide, diclofenac and
morphine were injected 45 to 60 minutes prior to the imple-
mentation of behavioral tests. All rats were trained on the end-
points during the week before the experiment started. The
animals were allowed to acclimate to the test room 15 minutes
prior the behavioral test. In the von Frey test, fibers were
applied after approximately 10 minutes habituation. Each
group was examined blind.
Evaluation of secondary tactile allodynia and mechanical 
hyperalgesia
For testing tactile secondary allodynia rats were placed on a
metallic grid floor. The nociceptive testing was done by insert-
ing the von Frey filament (Bioseb, Chaville, France) through
the grid floor and applying it to the plantar surface of the hind
paw. A trial consisted of several applications of the different
von Frey filaments, always to the same region of the paw at a
frequency of 1 to 1.5 s. The von Frey filaments applied were
from 10 g to 100 g. As soon as the animal removed its hind
paw, the test was stopped and the filament number was
recorded to represent the paw withdrawal threshold.
In the secondary mechanical hyperalgesia test, nociceptive
flexion reflexes were quantified using the Randall-Selitto paw
pressure device (Bioseb, Chaville, France), which applies a lin-
early increasing mechanical force to the dorsum of the rat's
hind paw. The paw withdrawal threshold was defined as the
force at which the rat withdrew its paw. The cut-off pressure
was set to 250 g.Available online http://arthritis-research.com/content/9/1/R14
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Drugs
Lacosamide was synthesized at Schwarz BioSciences GmbH
and morphine sulfate was obtained from Francopia (Paris,
France). The drugs were dissolved in saline. MIA and
diclofenac were purchased from Sigma (Lyon, France). Drug
administration was made in a volume of 1 ml/kg.
Data analyses and statistics
Comparisons of groups of behavioral data at each individual
time point were conducted using analysis of variance
(ANOVA) followed by post hoc analysis (Dunnett's test).
Results are presented as means and standard error of the
mean (SEM) and analyses revealing P values ≤ 0.05 were
deemed to be statistically significant.
Results
Histological analysis
At day 3 a substantial initial inflammatory response was visible
in the hematoxylin and eosin staining of the rat knee joints (Fig-
ure 1). This inflammation was characterized by an expansion of
the synovial membrane, most likely caused by proteinaceous
oedema fluid and fibrin with infiltrating macrophages, neu-
trophils, plasma cells and lymphocytes. As demonstrated in
the sections stained with safranin-O fast green, the cartilage
was still intact. On day 14 proteoglycan loss was seen
throughout the depth of the cartilage. The synovial membrane
looked normal and contained no inflammatory cells.
Figure 1
Histological analysis of synovial tissue and articular cartilage pre- and post-monosodium iodoacetate (MIA) injection Histological analysis of synovial tissue and articular cartilage pre- and post-monosodium iodoacetate (MIA) injection. Time course of histological 
changes of the rat knee before and days 3 and 14 after MIA injection. Left sections of the medial aspect of rat knee joints were stained with hema-
toxylin and eosin, right sections with safranin-O fast green. In non-arthritic rats no abnormality is present. On day 3 after MIA treatment the hematox-
ylin and eosin stained sections show significant expansion of the synovial membrane with a large amount of cellular infiltrate. No inflammation can be 
seen on day 14 post-MIA injection. The sections stained with safranin-O fast green reflect major cartilage degeneration on day 14 post-MIA injec-
tion. SM, synovial membrane; FE, femur; TI, tibia.Arthritis Research & Therapy    Vol 9 No 1    Beyreuther et al.
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Effect of drug treatment on secondary tactile allodynia
Tactile allodynia, tested with von Frey filaments, was assessed
at days 3, 7, and 14 in MIA-treated rats compared to control
rats (P < 0.05, Dunnett's test; Figures 2 and 3). Treatment
with lacosamide (30 mg/kg) and morphine (3 mg) significantly
improved the secondary mechanical allodynia of MIA-treated
rats at days 3 and 7 but not on day 14, whereas lower doses
only showed trends (P < 0.05, Dunnett's test; Figure 2). In the
control experiment with normal rats, treatment with 8, 16, and
32 mg/kg lacosamide had no effect on pain parameters in
comparison with vehicle rats (Figure 4). Diclofenac (30 mg)
had no effect on secondary mechanical allodynia at all time
points tested (P < 0.05, Dunnett's test; Figure 3).
Effect of drug treatment on secondary mechanical 
hyperalgesia
There was a marked secondary mechanical hyperalgesia, as
shown by a reduction in paw pressure withdrawal thresholds,
in the MIA/vehicle-treated animals compared to control/vehi-
cle treated animals (P < 0.05, Dunnett's test; Figures 5 and 6).
Treatment of MIA-treated rats with lacosamide 3 mg/kg,
diclofenac 30 mg/kg and morphine 3 mg/kg induced a signif-
icant increase (P < 0.05, Dunnett's test) in paw pressure with-
drawal threshold compared to MIA/vehicle-treated animals on
day 3. On day 7, lacosamide at all doses tested (3, 10 and 30
mg/kg), morphine and diclofenac reduced secondary mechan-
ical hyperalgesia. The same results were seen at day 14 after
MIA treatment except for the group treated with 10 mg/kg
lacosamide, which did not show a significant effect (P < 0.05,
Dunnett's test). Interestingly, in the MIA-treated animals,
secondary mechanical hyperalgesia developed from day 3 on
and lasted for at least 14 days compared to secondary tactile
allodynia, which was more pronounced during the early phase
of arthritis development, reflecting an ongoing development of
pain sensitization based on different molecular mechanisms
during the 14 days after MIA treatment.
Discussion
Osteoarthritis is a chronic condition widespread in the elderly
population. Patients with osteoarthritis have pain that typically
worsens with weight bearing and activity. The causes of oste-
oarthritis have not been fully determined, although biomechan-
ical forces affecting the articular cartilage and subchondral
bone, biochemical changes in the articular cartilage and syno-
vial membrane, and genetic factors are thought to be of impor-
tance [16]. Subchondral bone, periosteum, synovium,
ligaments, and the joint capsule are all richly innervated and
contain nerve endings that could be sources of nociceptive
stimuli [17,18]. In addition to peripheral pain sensitization, cen-
tral pain sensitization can occur in osteoarthritis [19]. Cur-
rently, no disease-modifying drugs are available so the
objective of pharmacological treatment has been aimed at
reducing pain, maintaining and/or improving joint mobility and
reducing functional impairment.
Figure 2
Effect of lacosamide and morphine on tactile allodynia after monoso- dium iodoacetate (MIA) injection Effect of lacosamide and morphine on tactile allodynia after monoso-
dium iodoacetate (MIA) injection. Effect of lacosamide and morphine on 
paw withdrawal threshold in the von Frey filament test in iodoacetate-
treated animals on (a) day 3, (b) day 7 and (c) day 14 after arthritis 
induction. Rats were tested 45 to 60 minutes post-drug. Data from 12 
animals/group are presented as mean ± SEM. *P < 0.05 Dunnett's test 
versus MIA/vehicle treated animals.Available online http://arthritis-research.com/content/9/1/R14
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Joint pain sensation may be caused in some states of osteoar-
thritis from free nerve endings in the synovium [20]. In the
iodoacetate rat model for osteoarthritis the initial period
implies a transient synovial inflammation. The role of macro-
phages in osteoarthritis has been stressed recently by Hay-
wood and co-workers [21]. One week after MIA treatment, the
inflammation is resolved in the joints and pain sensation is
more likely caused by biomechanical forces affecting the artic-
ular cartilage and subchondral bone. Therefore, the iodoace-
tate model reflects nicely the different pain states in
osteoarthritis patients.
In this study, as shown in previous publications [9,12,22], mor-
phine (3 mg/kg) inhibited secondary tactile allodynia and
mechanical hyperalgesia during the inflammatory as well as
non-inflammatory period after MIA treatment. The same is true
for lacosamide, which seemed to be more potent in inhibiting
secondary mechanical hyperalgesia (effect at 3 to 30 mg/kg)
than tactile allodynia (effect at 30 mg/kg).
Fernihough and colleagues [12] tested the anticonvulsant
gabapentin (100 mg/kg) in the iodoacetate model. Gabapen-
tin did not reduce pain behavior in the paw pressure test
(mechanical hyperalgesia) but had an effect on secondary tac-
tile allodynia at day 14 only. In the same study diclofenac, hav-
ing anti-inflammatory as well as analgesic activity, was not able
to reduce secondary mechanical allodynia at any time point
but had an effect on mechanical hyperalgesia at all time points
tested. In the present study diclofenac had no effect on sec-
ondary tactile allodynia as well but a significant reduction of
mechanical hyperalgesia could be seen. The cyclooxygenase
Figure 3
Effect of diclofenac on tactile allodynia after monosodium iodoacetate (MIA) injection Effect of diclofenac on tactile allodynia after monosodium iodoacetate (MIA) injection. Effect of diclofenac on paw withdrawal threshold in the von 
Frey filament test in iodoacetate-treated animals on days 3, 7 and 14 after arthritis induction. Rats were tested 45 to 60 minutes post drug. Data 
from12 animals/group are presented as mean ± SEM. *P < 0.05 Dunnett's test versus MIA/vehicle treated animals.
Figure 4
Tactile allodynia measurement in normal rats after lacosamide treatment Tactile allodynia measurement in normal rats after lacosamide treat-
ment. Effect of lacosamide on paw withdrawal threshold in the von Frey 
filament test in saline treated normal rats. Rats were tested 30 minutes 
post-drug. Data from eight animals/group are presented as mean ± 
SEM.Arthritis Research & Therapy    Vol 9 No 1    Beyreuther et al.
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inhibitor celecoxib (30 mg/kg) was able to reduce weight bear-
ing only after chronic treatment whereas rofecoxib (10 mg/kg)
reversed alterations in weight bearing after acute treatment
[8,22].
Lacosamide has also been analyzed in rat models in which
pain is induced by systemic inflammation [13]. Lacosamide
reversed carrageenan-induced mechanical hyperalgesia but
not the carrageenan-induced acute inflammatory response
(edema), suggesting that antinociception induced by lacosa-
mide is mainly mediated by interfering with pain transmission
rather than by providing anti-inflammatory effects. Lacosamide
had no effect on the non-inflamed paw in doses up to 40 mg/
kg. Gabapentin reversed carrageenan-induced hyperalgesia
with a minimal effective dose of 10 mg/kg for mechanical
hyperalgesia [23,24]. Pregabalin was active on carrageenan-
induced mechanical hyperalgesia with minimal effective doses
of 3 mg/kg and 6 mg/kg [23,24]. Lacosamide showed activity
against Freund's complete adjuvant-induced mechanical
hyperalgesia comparable to the effect of morphine [13]. In
contrast, gabapentin was only weakly active against Freund's
complete adjuvant-induced mechanical hyperalgesia [25,26].
Lacosamide was more potent than diclofenac on tactile allody-
nia and might be more potent than the anticonvulsants
gabapentin and pregabalin at inhibiting mechanical hyperalge-
sia in arthritis rat models.
These observations indicate that the effects of drugs on dis-
ease states differ depending on their mechanisms of action
and, therefore, have varying degrees of efficacy on the pathol-
ogy of the tested animal model. Multiple in vitro pharmacolog-
ical studies, for example, protein binding, functional receptor
and electrophysiology studies using classical anticonvulsant
targets, indicate that lacosamide does not share a common
mechanism of action with other anticonvulsant drugs [27,28].
The detailed mode of action of lacosamide will be further
explored. Future studies using longer term treatment with
lacosamide in the iodoacetate model should identify if
lacosamide has disease modifying activity in addition to its
antinociceptive activity.
Conclusion
Lacosamide had antinociceptive effects on both pain readouts
assessed in the MIA model for osteoarthritis during different
time points of pain development. The data presented in this
publication together with recently published animal study data
demonstrate lacosamide's ability to reduce arthritic pain
behavior induced by multiple mechanisms. This suggests that
lacosamide should be evaluated for the treatment of osteoar-
thritic pain in controlled clinical trails.
Competing interests
BKB and TS are employees of Schwarz BioSciences GmbH,
which is developing lacosamide for the treatment of diabetic
Figure 5
Effect of lacosamide and morphine on mechanical hyperalgesia after  monosodium iodoacetate (MIA) injection Effect of lacosamide and morphine on mechanical hyperalgesia after 
monosodium iodoacetate (MIA) injection. Effect of lacosamide and 
morphine on paw withdrawal threshold in the paw pressure test in MIA-
treated animals on (a) day 3, (b) day 7 and (c) day 14 after arthritis 
induction. Rats were tested 45 to 60 minutes post-drug. Data from 12 
animals/group are presented as mean ± SEM. *P < 0.05 Dunnett's test 
versus MIA/vehicle treated animals.Available online http://arthritis-research.com/content/9/1/R14
Page 7 of 8
(page number not for citation purposes)
neuropathic pain and epilepsy. BKB and TS are holders of pat-
ents relating to the content of this manuscript.
Authors' contributions
NC actively participated in the experimental and organizational
design of the study, developed the method for pain measure-
ments, and carried out or supervised the experiments. NC was
responsible for the evaluation of the data, as well as the statis-
tics, and reviewed the manuscript. BKB actively participated in
the experimental and organizational design of the study, gave
valuable advice for the evaluation and interpretation of the
experimental results, and drafted, revised, finalized, and sub-
mitted the manuscript. TS reviewed all experimental data, gave
valuable advice for the evaluation and interpretation of the
experimental results and the subsequent conclusions, and
reviewed the manuscript.
Acknowledgements
The authors gratefully acknowledge Emile Andriambelson and Julien 
Bindler for their support in performing the animal studies.
References
1. Witter J, Dionne RA: What can chronic arthritis pain teach about
developing new analgesic drugs?  Arthritis Res Ther 2004,
6:279-281.
2. Sarzi-Puttini P, Cimmino MA, Scarpa R, Caporali R, Parazzini F,
Zaninelli A, Atzeni F, Canesi B: Osteoarthritis: an overview of the
disease and its treatment strategies.  Semin Arthritis Rheum
2005, 35:1-10.
3. Felson DT: The sources of pain in knee osteoarthritis.  Curr
Opin Rheumatol 2005, 17:624-628.
4. Hinz B, Brune K: Pain and osteoarthritis: new drugs and
mechanisms.  Curr Opin Rheumatol 2004, 16:628-633.
5. Bendele AM: Animal models of osteoarthritis.  J Musculoskelet
Neuronal Interact 2001, 1:363-376.
6. Guzman RE, Evans MG, Bove S, Morenko B, Kilgore K: Mono-
iodoacetate-induced histologic changes in subchondral bone
and articular cartilage of rat femorotibial joints: an animal
model of osteoarthritis.  Toxicol Pathol 2003, 31:619-624.
7. Kalbhen DA: Chemical model of osteoarthritis – a pharmaco-
logical evaluation.  J Rheumatol 1987, 14:130-131.
8. Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE,
Juneau PL, Schrier DJ, Kilgore KS: Weight bearing as a measure
of disease progression and efficacy of anti-inflammatory com-
pounds in a model of monosodium iodoacetate-induced
osteoarthritis.  Osteoarthritis Cartilage 2003, 11:821-830.
9. Combe R, Bramwell S, Field MJ: The monosodium iodoacetate
model of osteoarthritis: a model of chronic nociceptive pain in
rats?  Neurosci Lett 2004, 370:236-240.
10. Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P, Gil-
let P: Mono-iodoacetate-induced experimental osteoarthritis:
a dose–response study of loss of mobility, morphology, and
biochemistry.  Arthritis Rheum 1997, 40:1670-1679.
11. Kobayashi K, Imaizumi R, Sumichika H, Tanaka H, Goda M, Fuku-
nari A, Komatsu H: Sodium iodoacetate-induced experimental
osteoarthritis and associated pain model in rats.  J Vet Med Sci
2003, 65:1195-1199.
12. Fernihough J, Gentry C, Malcangio M, Fox A, Rediske J, Pellas T,
Kidd B, Bevan S, Winter J: Pain related behaviour in two models
of osteoarthritis in the rat knee.  Pain 2004, 112:83-93.
13. Stohr T, Krause E, Selve N: Lacosamide displays potent antino-
ciceptive effects in animal models for inflammatory pain.  Eur
J Pain 2006, 10:241-249.
14. Beyreuther B, Callizot N, Stohr T: Antinociceptive efficacy of
lacosamide in a rat model for painful diabetic neuropathy.  Eur
J Pharmacol 2006, 539:64-70.
15. McCleane G, Koch B, Rauschkolb C: Does SPM927 have an
analgesic effect in human neuropathic pain? An open label
study.  Neurosci Lett 2003, 352:117-120.
16. Holderbaum D, Haqqi TM, Moskowitz RW: Genetics and oste-
oarthritis: exposing the iceberg.  Arthritis Rheum 1999,
42:397-405.
17. Heppelmann B: Anatomy and histology of joint innervation.  J
Peripher Nerv Syst 1997, 2:5-16.
18. Mach DB, Rogers SD, Sabino MC, Luger NM, Schwei MJ,
Pomonis JD, Keyser CP, Clohisy DR, Adams DJ, O'Leary P, Mantyh
PW: Origins of skeletal pain: sensory and sympathetic inner-
vation of the mouse femur.  Neuroscience 2002, 113:155-166.
19. Schaible HG, Ebersberger A, Von Banchet GS: Mechanisms of
pain in arthritis.  Ann NY Acad Sci 2002, 966:343-354.
20. Saito T, Koshino T: Distribution of neuropeptides in synovium
of the knee with osteoarthritis.  Clin Orthop Relat Res 2000,
376:172-182.
21. Haywood L, McWilliams DF, Pearson CI, Gill SE, Ganesan A, Wil-
son D, Walsh DA: Inflammation and angiogenesis in
osteoarthritis.  Arthritis Rheum 2003, 48:2173-2177.
Figure 6
Effect of diclofenac on mechanical hyperalgesia after monosodium iodoacetate (MIA) injection Effect of diclofenac on mechanical hyperalgesia after monosodium iodoacetate (MIA) injection. Effect of diclofenac on paw withdrawal threshold in 
the paw pressure test in MIA-treated animals on days 3, 7 and 14 after arthritis induction. Rats were tested 45 to 60 minutes post-drug. Data from 
12 animals/group are presented as mean ± SEM. *P < 0.05 Dunnett's test versus MIA/vehicle treated animals.Arthritis Research & Therapy    Vol 9 No 1    Beyreuther et al.
Page 8 of 8
(page number not for citation purposes)
22. Pomonis JD, Boulet JM, Gottshall SL, Phillips S, Sellers R, Bunton
T, Walker K: Development and pharmacological characteriza-
tion of a rat model of osteoarthritis pain.  Pain 2005,
114:339-346.
23. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L:
Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a
novel class of selective antihyperalgesic agents.  Br J
Pharmacol 1997, 121:1513-1522.
24. Hurley RW, Chatterjea D, Rose Feng M, Taylor CP, Hammond DL:
Gabapentin and pregabalin can interact synergistically with
naproxen to produce antihyperalgesia.  Anesthesiology 2002,
97:1263-1273.
25. Nagakura Y, Okada M, Kohara A, Kiso T, Toya T, Iwai A, Wanibuchi
F, Yamaguchi T: Allodynia and hyperalgesia in adjuvant-
induced arthritic rats: time course of progression and efficacy
of analgesics.  J Pharmacol Exp Ther 2003, 306:490-497.
26. Patel S, Naeem S, Kesingland A, Froestl W, Capogna M, Urban L,
Fox A: The effects of GABA(B) agonists and gabapentin on
mechanical hyperalgesia in models of neuropathic and inflam-
matory pain in the rat.  Pain 2001, 90:217-226.
27. Errington AC, Coyne L, Stohr T, Selve N, Lees G: Seeking a
mechanism of action for the novel anticonvulsant lacosamide.
Neuropharmacology 2006, 50:1016-1029.
28. Lees G, Stohr T, Errington AC: Stereoselective effects of the
novel anticonvulsant lacosamide against 4-AP induced epilep-
tiform activity in rat visual cortex in vitro.  Neuropharmacology
2006, 50:98-110.